| Scibase

Nov 07 2025

Interim report

January 1 - September 30, 2025

The third quarter in figures

Net sales were TSEK 10,339 (8,408), +23%, cleared for currency effects +29%.
The loss after tax was TSEK 18,832 (17,753).
The loss per share was SEK 0.05 (0.08).
The cash flow from current operations was negative in the amount of TSEK 17,287 (16,745).
The gross margin was 60.0% (75.7%).
Electrode sales volume increased by 24% and was 21,278 (17,210) units. Repeat sales of electrodes to existing customers increased by 33%.

The first nine months in figures

Net sales were TSEK 27,987 (21,107), +33%, cleared for currency effects +38%.
The loss after tax was TSEK 72,932 (43,663).
The loss per share was SEK 0.21 (0.27).
The cash flow from current operations was negative in the amount of TSEK 63,754 (44,835).
The gross margin was 65.3% (72.0%).
Electrode sales volume increased by 28% and was 57,546 (45,078) units. Repeat sales of electrodes to existing customers increased by 31%.

Important events during the quarter

Overall sales increased by 23% (+29%, before currency effects). Sales in Germany within the skin cancer segment increased by 17% (20% in local currency). Sales in the US skin cancer market increased by 97% (116% in local currency) while the sales within the skin barrier segment decreased by 65%, Q3-24 included a large order to NIH in the US.
The gross margin was in the quarter negatively affected by the currency development (negative impact of around 2%), higher number of devices sold free of charge in Germany, increased price on gold and temporarily a lower yield following ramp-up of production with new employees.

SciBase received the initial order for a clinical study under the collaboration with Castle Biosciences. The order consists of Nevisense Go and electrodes to a value of around $0.8 million or approximately MSEK 8. Deliveries are expected to start in Q4 2025.

Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis.

New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense.

A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.

A new Nevisense pilot was launched at leading University in Southeast Florida.

The directed issue to Castle Biosciences was finalized and raised MSEK 19.

Important events after the end of the period

SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement.

The Board of SciBase resolves to decide on a rights issue of approximately SEK 83m and decides on an offer to convert outstanding TO2 warrants into shares.

A Nomination Committee has been appointed for SciBase Holding’s Annual General Meeting in 2026.

					Oct 1, 2024 -
	July 1 - Sep 30		Jan 1 - Sep 30		Sep 30, 2025	Jan 1 - Dec 31
THE GROUP	2025	2024	2025	2024	Rolling-12	2024
Net sales, SEK ths	10 339	8 408	27 987	21 107	36 584	29 705
Gross margin, %	60,0%	75,7%	65,3%	72,0%	66,0%	71,0%
Equity/Asset ratio, %	62,0%	67,6%	62,0%	67,6%	64,8%	59,4%
Net indebtness, multiple	0,61	0,48	0,61	0,48	0,54	0,68
Cash equivalents, SEK ths	24 757	24 714	24 757	24 714	24 757	11 245
Cashflow from operating activities, SEK ths	-17 287	-16 475	-63 754	-44 835	-76 302	-57 383
Earnings per share (before and after dilution), SEK	-0,05	-0,08	-0,21	-0,27	-0,29	-0,34
Shareholder's equity per share, SEK	0,09	0,17	0,10	0,23	0,11	0,21
Average number of shares, 000'	390 239	219 538	342 415	164 146	311 696	177 994
Number of shares at closing of period, 000'	414 183	219 538	414 183	219 538	414 183	219 538
Share price at end of period, SEK	0,38	0,48	0,38	0,51	0,38	0,41
Number of sold electrodes, pieces	21 278	17 210	57 546	45 078	74 678	62 210
Average number of employees	34	29	35	27	33	28

This information is information that SciBase Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 7 November 2025.

This report has been comprehensively reviewed by the Company’s auditors.

For further information please contact:

Pia Renaudin, CEO,
Phone. +46732069802
E-mail: [email protected]

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Nov 07 2025

The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million

The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534,835 outstanding warrants of series TO 2 in the Company (the "TO 2 Offer"). In the TO 2 Offer, two (2) warrants of series TO 2 will entitle the holder to one (1) new share in the Company. Through the TO 2 Offer, a total of 249,267,417 new shares may be issued. A group of investors who holds warrants of series TO 2 have, in total, entered into irrevocable undertakings to tender a total of 368 709 753 warrants of series TO 2 in the TO 2 Offer, which corresponds to around 74 percent of the total number of outstanding warrants of series TO 2. The TO 2 Offer is conditional upon an extraordinary general meeting in the Company resolving to authorise the Board of Directors to issue new shares. An extraordinary general meeting is intended to be held on 5 December 2025 and a notice to convene the extraordinary general meeting will be announced through a separate press release. Furthermore, the Board of Directors today announces its intention to resolve on a new share issue, with preferential rights for the Company's shareholders, of approximately SEK 83 million, pursuant to the authorisation granted by the annual general meeting held on 17 June 2025 (the "Rights Issue"). The Rights Issue is covered by subscription undertakings to an aggregate amount of approximately SEK 64.3 million, corresponding to approximately 78 percent of the Rights Issue.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE DONE WITHOUT APPLICATION OF EXEMPTIONS FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

Summary of the TO 2 Offer

For two (2) warrants of series TO 2 (where one (1) warrant of series TO 2 entitles the holder to subscription of one (1) new share), one (1) new share is received.
In the TO 2 Offer, the Company's shares have been valued at SEK 0.20 per share (which corresponds to the subscription price in the intended Rights Issue) and warrants of series TO 2 have been valued at SEK 0.10 per warrant.
The TO 2 Offer can result in a maximum of 249,267,417 new shares being issued, representing a maximum dilution of approximately 37.6 percent (calculated on the total number of outstanding shares in the Company after the completion of the TO 2 Offer).
The minimum possible number of warrants of series TO 2 to transfer in the TO 2 Offer is two (2) warrants of series TO 2.
A group of investors who holds warrants of series TO 2 have, in total, entered into irrevocable undertakings to tender a total of 368 709 753 warrants of series TO 2 in the TO 2 Offer, which corresponds to approximately 74 percent of total number of outstanding warrants of series TO 2.
The acceptance period for the TO 2 Offer is intended to commence on 8 December 2025 and run until, and including, 8 January 2026.
Shares issued as a result of the TO 2 Offer will be registered and delivered in connection with the registration of the Rights Issue. Hence, the shares issued as a result of the TO 2 Offer will not entitle to participation in the Rights Issue.

Summary of the Rights Issue

The Board of Directors today announces its intention to resolve on the Rights Issue of approximately SEK 83 million, before deduction of transaction costs.
The net proceeds from the Rights Issue are predominately intended to be used to finance continued commercialisation activities with focus on the US market and are expected to finance SciBase well into 2027.
All existing shareholders are intended to receive one (1) subscription right for each share held on the record date of 8 January 2026. One (1) subscription right is intended to entitle the holder to subscribe for one (1) new share in the Company at a subscription price of 0.20 SEK per share.
The Rights Issue is covered by subscription undertakings to an aggregate amount of approximately SEK 64.3 million, corresponding to approximately 78 percent of the Rights Issue.
The subscription undertakings from persons from the Board of Directors and senior management of the Company amount to approximately SEK 0.7 million, corresponding to approximately 0.9 percent of the Rights Issue.
In addition to subscribing for their respective pro-rata share in the Rights Issue, Castle Bioscience and Hagagruppen have undertaken to subscribe for an additional SEK 24.9 million in the Rights Issue without the support of subscription rights, equivalent to approximately 30.1 percent of the Rights Issue.
The subscription period in the Rights Issue is expected to commence on 12 January 2026 and run to, and including, 26 January 2026.
The Board of Directors intends to resolve on the Rights Issue on or around 29 December 2025.

"SciBase is developing well with a growing and profitable operation in Germany and rapid growth in the US. In addition to our strong performance within melanoma diagnostics, we are accelerating our activities in other skin diseases together with Castle Biosciences. The upcoming Rights Issue will provide runway for continued growth that will set us on a course towards profitability. There is a strong support for the Rights Issue with pro-rata commitments totalling 48 percent of the Rights Issue. We also have a strong support from Castle Biosciences, who has committed to invest SEK 23m in addition to their pro-rata share of the Rights Issue. The capital from the Rights Issue will finance SciBase well into 2027 and enable us to continue our growth journey. Furthermore, the TO 2 Offer will significantly improve our capital structure and facilitate future capital raises" says Pia Renaudin, CEO of SciBase.

The TO 2 Offer

In April 2024, SciBase carried out a directed issue and a rights issue raising approximately SEK 48 million. In the issues, a total of 498,534,835 warrants of series TO2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.42 in April 2029. Currently, the number of outstanding warrants of series TO 2 surpasses the number of outstanding shares in the Company (498,534,835 warrants of series TO2 compared to 414,182,583 shares) and thus represents a significant potential future dilution. As the warrants of series TO 2 expire in 2029, they are not expected to contribute with capital to SciBase in the near term.

In discussions with the Company's major shareholders and external potential investors, it has emerged that there is an interest in having the opportunity to exchange warrants of series TO 2 for shares, meaning that the number of outstanding warrants of series TO 2 and potential dilution decreases significantly. Reducing dilution is also something that other investors, who currently do not own shares in the Company, have expressed could positively affect the willingness to invest in the Company's shares. Prior to the resolution on the TO 2 Offer, the Board of Directors has placed great emphasis on ensuring that the exchange ratio and valuation of the instruments should be market-based in relation to the prevailing share price and the market value of the Company's outstanding warrants of series TO 2. The price per share and the valuation of the warrants of series TO 2 in the TO 2 Offer have been determined by the Board of Directors, in consultation with the financial advisors, after arm's length negotiations with the investors, whereby the Board of Directors has considered several factors such as market conditions, the Company's financing needs and alternative cost for other financing, as well as assessed market interest for an investment in the Company. In accordance with the considerations above, the Board of Directors has resolved to carry out the TO 2 Offer where the warrant holders have the opportunity to convert their warrants of series TO 2 into new shares in the Company.

For two (2) warrants of series TO 2 (where one (1) warrant of series TO 2 entitles the holder to subscription of one (1) new share), one (1) new share is received in the TO 2 Offer. The minimum possible number of warrants of series TO 2 to transfer in the Offer is two (2) warrants of series TO 2. In the TO 2 Offer, the Company's shares have been valued at SEK 0.20 per share (which corresponds to the subscription price in the intended Rights Issue) and warrants of series TO 2 have been valued at SEK 0.10 per warrant.

The acceptance period for the TO 2 Offer is intended to commence on 8 December 2025 and run until, and including, 8 January 2026.

Shares issued as a result of the TO 2 Offer will be registered and delivered in connection with the registration of the Rights Issue. Hence, the shares issued as a result of the TO 2 Offer will not entitle to participation in the intended Rights Issue.

A group of investors who holds warrants of series TO 2, including, amongst others, Ribbskottet, Ejendal Industri and Life Science Investment Fund 1, have, in total, entered into irrevocable undertakings to tender a total of 368 709 753 warrants of series TO 2 in the TO 2 Offer, which corresponds to approximately 74 percent of total number of outstanding warrants of series TO 2.

Subscription of shares in accordance with the TO 2 Offer will in practice be made through subscription of shares in a directed set-off issue of new shares to the holders of warrants of series TO 2 that have accepted the TO 2 Offer (the "Set-off Issue"). The Board of Directors intends to resolve on the Set-off Issue after the acceptance period for the TO 2 Offer has ended. Thus, the TO 2 Offer is conditional upon the extraordinary general meeting, intended to be held on or around 5 December 2025, resolving to authorise the Board of Directors to resolve on the Set-off Issue. A notice to convene the extraordinary general meeting will be announced through a separate press release.

If the TO 2 Offer is fully accepted, a maximum of 249,267,417 new shares can be issued, corresponding to a maximum dilution of approximately 37.6 percent (calculated on the total number of outstanding shares in the Company if the TO 2 Offer is fully accepted).

Further information regarding the TO 2 Offer and the acceptance procedure will be presented in the information document that will be published prior to the commencement of the acceptance period in the TO 2 Offer.

Indicative timeline for the TO 2 Offer

Expected date for the extraordinary general meeting	5 December 2025
Publication of the information document related to the TO 2 Offer	On or around 5 December 2025
Acceptance period	8 December 2025 – 8 January 2026
Expected announcement of the outcome of the TO 2 Offer	9 January 2026

Background and reasons for the Rights Issue and use of proceeds

SciBase is a medical technology company specializing in early detection and prevention in dermatology through the commercialization of Nevisense, a patient-centric platform that combines AI and EIS technology (Electrical Impedance Spectroscopy) to increase diagnostic accuracy and thereby ensure the prevention of skin diseases.

Within melanoma diagnostics, SciBase has a well-established and increasing position in the German market with more than 400 systems installed generating recurring revenues from the sale of electrodes used for each patient. Currently, on an annual basis, the German market generates revenues of more than SEK 20 million at an operational profitability.

Since 2024, SciBase has increased its efforts in the US market resulting in a strong growth driven by an increasing number of installed systems as well as increased usage. In the first nine months 2025, revenues in the US grew by more than 200 percent.

Based on current operations, SciBase need to reach an installed base of 800 to 1 000 systems with a utilization rate of 5-7 electrodes per week in order to reach break-even. Together with more than 200 active systems in the German market, the strong momentum in the US will, according to the Company, bring the Company towards the installed base needed for profitability.

In addition to a strong growth within melanoma diagnostics, SciBase has recently expanded its activities within diagnostics of Atopic dermatitis and other skin diseases through the collaboration with US diagnostics company Castle Bioscience that was announced in June this year. The collaboration with Castle Bioscience is developing well and as announced in a separate press release today, the parties have agreed to expand the collaboration and accelerate activities in additional indications. As part of the expanded collaboration, Castle Bioscience will provide SciBase with a long-term debt facility of SEK 20 million that will finance investments into production ramp-up to meet Castle Bioscience’s need for Nevisense systems.

In order to support the Company's strategy and opportunities to achieve its future commercial and financial goals, the Board of Directors intends to resolve on the Rights Issue. The net proceeds from the Rights Issue are predominately intended to be used to finance continued commercialisation activities with focus on the US market. As a secondary focus, SciBase intends to continue to build on the success in the German market through expansion into adjacent markets including Austria, Switzerland and Italy.

The Rights Issue

Shareholders who are registered in the share register in SciBase on the record date on 8 January 2026 will receive one (1) subscription right for each share held in the Company. One (1) subscription right entitles the holder to subscribe for one (1) new share. The subscription price is set at SEK 0.20 per share, which means that SciBase will receive gross proceeds of approximately SEK 83 million before deduction of transaction costs, provided that the Rights Issue is fully subscribed. In addition, investors are offered the opportunity to apply for subscription of shares in the Rights Issue without the support of subscription rights.

The subscription period in the Rights Issue, with or without the support of subscription rights, is expected to run from and including 12 January 2026 up to and including 26 January 2026, or such later dated resolved by the Board of Directors. The last day of trading in SciBase's shares including the right to receive subscription rights in the Rights Issue is expected on 5 January 2026. The shares are expected to be traded excluding the right to receive subscription rights in the Rights Issue as of 7 January 2026. Trading in subscription rights is expected to take place on Nasdaq First North Growth Market during the period from and including 12 January 2026 up to and including 21 January 2026 and trading in BTAs (paid subscribed share) will take place on Nasdaq First North Growth Market during the period from and including 12 January 2026 until on or around 13 February 2025 (following the registration of the Rights Issue with the Swedish Companies Registration Office).

In the event all shares in the Rights Issue are not subscribed for with the support of subscription rights, the Board of Directors shall, within the maximum amount of the Rights Issue, resolve on the allotment of shares subscribed for without the support of subscription rights in accordance with the following allotment principles:

Firstly, allocation shall be made to those who subscribed for shares with the support of subscription rights, regardless of whether the subscriber was a shareholder on the record date or not, and, in case of oversubscription, in relation to the number of subscription rights that each party has exercised for subscription of shares, and, if this is not possible, by drawing lots.
Secondly, allocation shall be made to other subscribers who subscribed for shares without the support of subscription rights, and, in case of oversubscription, in relation to the subscribed amount, and, if this is not possible, by drawing lots.

If the Rights Issue is fully subscribed, a maximum of 414,182,583 new shares can be issued, corresponding to a maximum dilution of 50.0 percent of the total number of shares and votes in the Company (calculated on the total number of outstanding shares in the Company if the Rights Issue is fully subscribed). Shareholders have the opportunity to compensate themselves financially for this dilution effect by selling their received subscription rights.

Indicative timeline for the Rights Issue

Last day of trading in shares including right to receive subscription rights	5 January 2026
First day of trading in shares excluding right to receive subscription rights	7 January 2026
Estimated date for publication of the information document related to the Rights Issue	On or around 9 January 2026
Record date in the Rights Issue	8 January 2026
Trading in subscription rights	12 – 21 January 2026
Subscription period	12 – 26 January 2026
Trading in paid subscribed shares (BTA)	From 12 January 2026 until on or around 13 February 2026
Expected announcement of the outcome in the Rights Issue	27 January 2026

Number of shares and share capital

If the TO 2 Offer is fully accepted, the Company's share capital increases by SEK 12,463,370.85 through the issuance of 249,267,417 new shares. If the Rights Issue is fully subscribed, the Company's share capital increases by SEK 20,709,129.15 through the issuance of 414,182,583 new shares.

Provided that the TO 2 Offer is fully accepted and the Rights Issue is fully subscribed, the total dilution effect for existing shareholders corresponds to approximately 61.6 percent (calculated on the total number of outstanding shares in the Company following a fully accepted TO 2 Offer and a fully subscribed Rights Issue).

Subscription undertakings and declaration of intent

Several existing shareholders including Ribbskottet, Castle Bioscience, Haga Gruppen, Praktikerinvest and members of the Company’s Board of Directors and management have undertaken to subscribe for shares in the Rights Issue to an approximate aggregate amount of SEK 39,4 million, corresponding to approximately 47.6 percent of the Rights Issue. Furthermore, additional shareholders representing around 7.8 percent of the shares in the Company have expressed their intent to subscribe in full or to a large extent (>50 percent) in the Rights Issue.

In addition to subscribing for its pro-rata share in the Rights Issue, Castle Bioscience has undertaken to subscribe for an additional SEK 23 million in the Rights Issue without the support of subscription rights, equivalent to approximately 27.8 percent of the Rights Issue. Castle Bioscience’s subscription undertaking is, however, conditional upon Castle Bioscience’s ownership of the Company, following the Rights Issue and TO 2 Offer, being less than 20 percent of the total number of outstanding shares in the Company. Furthermore, in addition to subscribing for its pro-rata share in the Rights Issue, Haga Gruppen Holding has undertaken to subscribe for an additional SEK 1.9 million in the Rights Issue, equivalent to approximately 2,3 percent of the Rights Issue.

In total, the Rights Issue is covered by subscription undertakings to an approximate amount of SEK 64.3 million, corresponding to approximately 77.6 percent of the Rights Issue. No compensation is paid for the subscription undertakings. The undertakings are not secured by bank guarantees, blocked funds, pledged assets or similar arrangements.

Further information regarding the subscription undertakings in the Rights Issue will be presented in the information document that will be published prior to the commencement of the subscription period in the Rights Issue.

Information document

In connection with the TO 2 Offer and the Rights Issue, respectively, the Company is preparing information documents in accordance with Article 1(4)(db) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC (the "Prospectus Regulation"). The information documents are prepared in accordance with Annex IX to the Prospectus Regulation. One information document regarding the TO 2 Offer is expected to be published on or around 5 December 2025 and one information document regarding the Rights Issue is expected to be published on or around 9 January 2026.

Further information regarding the TO 2 Offer and the Rights Issue, respectively, and information about the Company will be provided in the information documents which are expected to be published on the Company's website on or around 5 December 2025 and on or around 9 January 2025, respectively.

Extraordinary general meeting

The TO 2 Offer is conditional upon an extraordinary general meeting in the Company resolving to authorise the Board of Directors to issue new shares. An extraordinary general meeting is intended to be held on 5 December 2025 and a notice to convene the extraordinary general meeting will be announced through a separate press release.

FDI Act

The Company considers that it conducts activities worthy of protection under the Foreign Direct Investment Review Act (2023:560) (the "FDI Act"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the Swedish Inspectorate for Strategic Products (the "ISP") prior to its realization. An investment may be notifiable if (i) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, after the investment is made, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total voting rights in the Company, (ii) the investor acquires the Company through the investment and the investor any member of its ownership structure or any person on whose behalf the investor is acting, directly or indirectly, would hold 10 percent or more of the total voting rights in the Company; and iii) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, would acquire through the investment a direct or indirect influence in the management of the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either (i) resolved to leave the notification without action or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue and the TO 2 Offer for the individual shareholder.

Advisors

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisors and Advokatfirman Schjødt as legal advisor in connection with the Rights Issue and the TO2 Offer.

For more information, please contact:
Jesper Høiland, Chairman of the board, phone +45 612 207 30

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information:

The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction.

The availability of the TO 2 Offer and the Rights Issue to holders who are not resident Sweden may be affected by the laws of the relevant jurisdiction in which they are located. Holders who are not resident in Sweden should inform themselves about and observe any applicable legal and regulatory requirements.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in SciBase in any jurisdiction, neither from SciBase nor from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue or the TO 2 Offer. The Company will prepare and publish one information document in the form prescribed in Annex IX to the Prospectus Regulation regarding the Rights Issue and one information document in the form prescribed in Annex IX to the Prospectus Regulation regarding the TO 2 Offer. The information documents will be available on the Company's website (https://investors.scibase.se).

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this press release is for the purpose of describing the background to the Rights Issue and the TO 2 Offer, respectively, only and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information contained in this press release.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

The TO 2 Offer relates to securities in a non-US company and is subject to the disclosure requirements, rules and practices applicable to companies listed in Sweden, which differ from those of the United States in certain material respects. The TO 2 Offer is not subject to the disclosure and other procedural requirements of Regulation 14D under the US Exchange Act of 1934, as amended (the "Exchange Act"). The TO 2 Offer will be made solely to qualifying US holders in the United States in accordance with the requirements of Regulation 14E under the US Exchange Act to the extent applicable and subject to any exemptions or relief therefrom. Certain provisions of Regulation 14E under the Exchange Act are not applicable to the TO 2 Offer by virtue of the Tier II exemptions provided by Rule 14d-1(d) under the Exchange Act.

The Company considers that it conducts activities worthy of protection under the FDI Act. In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. In the event that an investment is notifiable, it must be notified to the ISP prior to its realization. An investment may be notifiable if (i) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, after the investment is made, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total voting rights in the Company, (ii) the investor acquires the Company through the investment and the investor any member of its ownership structure or any person on whose behalf the investor is acting, directly or indirectly, would hold 10 percent or more of the total voting rights in the Company; and iii) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, would acquire through the investment a direct or indirect influence in the management of the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either (i) resolved to leave the notification without action or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue and the TO 2 Offer for the individual shareholder.

Forward-looking statements

Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not refer to historical facts and events, as well as statements that refer to the future and for example contain expressions such as "anticipates", "intends", "may', "will", "should", "estimates", "believes", "may", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results of operations, financial condition, cash flows, plans and expectations of the Company's business and management, future growth and profitability and the general economic and regulatory environment and other circumstances affecting the Company, many of which are in turn based on additional assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which individually or in the aggregate could be material to the Company's results of operations or its ability to operate its business. Although the Company believes that these assumptions were reasonable when made, they are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and may be beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Accordingly, prospective investors should not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly advised to read those parts of the information documents that include a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements contained in this press release is valid only as of the date of this press release and is subject to change without notice.

Nov 07 2025

SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million

STOCKHOLM, Sweden - November 7, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase and Castle Biosciences ("Castle") (Nasdaq: CSTL) have expanded their collaboration and license agreement and entered into a separate loan agreement. The two companies first entered into the collaboration and license agreement in June 2025. The expanded agreement includes providing Castle increased autonomy over the manufacturing process. Under the separate loan agreement, Castle will provide SEK 20 million to SciBase.

The goal of the first joint clinical study is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD), with additional indications to potentially follow. The loan is based on market terms with a potential for Castle to request conversion of the loan into new shares.

"Our collaboration with Castle Biosciences is moving ahead at full speed," said Pia Renaudin, CEO of SciBase. "With this loan, we secure the resources needed to smoothly ramp up production and maintain uninterrupted growth. We expect the resulting improvements in product margins will create value across all markets and indications. This collaboration will also help us accelerate the adoption of Nevisense in skin barrier health and continue driving strong sales growth in skin cancer diagnostics."

The loan agreement is a five-year loan amounting to SEK 20 million. The interest rate on the loan amounts to STIBOR plus two (2) per cent per annum and shall be paid quarterly. However, the first interest payment date shall be 31 March 2026, and the final interest payment date shall be on the repayment date of the loan. The loan shall be repaid in cash no later than five years following the signing of the loan agreement or, if demanded by Castle, by way of conversion of the loan amount into new shares in SciBase. In case of conversion, the conversion price per share shall correspond to the volume weighted average price of the shares in SciBase during the 30 trading days preceding the repayment date. For the avoidance of doubt, repayment of the loan may be made in a combination of cash repayment and conversion repayment. The loan is secured by a share pledge over SciBase's shares in SciBase AB.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CEST on November 7, 2025.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic treatment decision making for patients with moderate-to-severe atopic dermatitis. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

For further information please contact:

Pia Renaudin, CEO,
Phone. +46732069802
E-mail: [email protected]

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)
Tel: ++46 8 588 68 570
E-mail: [email protected]

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------

Oct 22 2025

Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2026

The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2026:

Anders Bladh (Ribbskottet AB),

Derek Maetzold (Castle Biosciences Inc)

Maria Anderkvist (Coeli Wealth Management),

Jesper Høiland (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2025.

The Annual General Meeting of SciBase Holding AB (publ) will be held on May 19, 2026 in Stockholm.

Shareholders who wish to have an item considered by the nominating committee can do this in writing to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm or by e-mail to [email protected] Att: Chairman of the Board (who is the convenor of the nominating committee).

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Stockholm, October 22, 2025

SciBase Holding AB (publ)

For more information, please contact:
Jesper Høiland, Chairman of the board, phone +45 612 207 30

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Sep 26 2025

Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis

SWEDEN - September 26, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used in an atopic dermatitis model to assess factors in human excised skin samples, demonstrating Nevisense to measure skin barrier integrity and monitor changes to the skin barrier function during inflammatory states, such as during eczema and atopic dermatitis.

In the study, human ex vivo skin samples were exposed to inflammatory cytokines IL-4, IL-13 and IL-22, resembling a similar inflammatory response in skin lesions from patients with atopic dermatitis. Nevisense EIS measurements showed to be highly sensitive to detect this inflammatory disruption of the skin barrier function over time. Pivotal genes that play a role in skin barrier changes and type-2 response have been identified. More importantly, genes involved in the restoration of skin inflammation and barrier function by medication with dupilumab were identified in the study. The study therefore emphasizes the potential of Nevisense to be used in measuring and monitoring skin barrier integrity during different disease states of atopic dermatitis, including treatment monitoring.

Skin barrier research is a fast-growing field in dermatology, including the development of new diagnostic methods, therapeutics, aesthetic products, and scientific investigations of diseases related to the skin barrier. Disruption of skin barrier function plays a key role in the development and severity of several skin diseases such as atopic dermatitis.

"We are very encouraged to see that EIS measurements could determine skin barrier integrity and monitor changes to the skin barrier function during type 2 and non type 2 skin inflammation in an atopic dermatitis model. EIS provides an increasingly useful tool for the better understanding of molecular mechanisms of skin barrier integrity" said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research).

"We are happy to see that Nevisense and the EIS-technology continue to provide value in this type of research. This study further strengthens the role of Nevisense as an effective research device and show the potential to become the state-of-the-art research tool within the skin barrier research," said Pia Renaudin, CEO of SciBase.

The full results of the study have now been published in the scientific journal Allergy "Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis" - D'Avino - Allergy, DOI: http://doi.org/10.1111/all.70060.

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Sep 23 2025

SciBase receives initial order for clinical study from Castle Biosciences

SWEDEN - September 23, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received the initial order for a clinical study under the collaboration with Castle Biosciences. The order consists of Nevisense Go and electrodes to a value of around $0.8 million or approximately MSEK 8.

As previously announced on June 16th, 2025, SciBase has entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The initial collaboration project is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). This order is for products to be used in a clinical study for the first project. Deliveries are expected to start in Q4 2025.

As outlined in the collaboration agreement, Castle invested in SciBase and is now SciBase’s second largest shareholder.

"The collaboration with Castle Biosciences is moving forward at a fast pace and this first order signals the initiation of our first joint study," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Sep 10 2025

Main owners strengthen their position in SciBase

SWEDEN - September 10, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet AB, the company's largest owner, and Life Science Investment Fund, each has purchased approximately 7.5 million shares in SciBase in a block trade which occurred on Tuesday off the stock exchange from larger long-term owners.

"SciBase continues to impress through rapid growth and interesting collaborations, most recently with Castle Biosciences Inc, while the market still does not seem to have grasped what SciBase is achieving in skin and cancer analysis. When this stake emerged at an attractive price, Ribbskottet therefore did not hesitate to increase its position in the company," said Anders Bladh CEO of Ribbskottet AB.

Jan Poulsen, CEO at Life Science Invest Fund (LSIF), says: "With this additional investment we are happy to strengthen our ownership in SciBase as we believe SciBase is on track for an exciting journey in the coming years and is a very compelling investment case at this low valuation".

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570 E-mail: [email protected]

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Aug 28 2025

New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense

SWEDEN - August 28, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication of the article "The Importance of Reader Studies in Dermatology" by Dr. Alexander Meves from the Mayo Clinic, in the peer-reviewed journal Dermatology by Karger (DOI: 10.1159/000548165). The article underscores the value of reader studies in validating new dermatology technologies, with Nevisense, SciBase's electrical impedance spectroscopy (EIS) system, featured as a key example.

Reader studies are a well-established methodology across medicine-in radiology, cardiology, and pathology-used to evaluate diagnostic accuracy and ensure new technologies perform reliably in real-world practice. The publication confirms that Nevisense improves biopsy decision-making for suspicious pigmented lesions and enhances diagnostic accuracy.

"Reader studies have long been a gold standard across medicine to validate diagnostic technologies in real-world settings," said Dr. Alexander Meves, Department of Dermatology, Mayo Clinic. "Our findings show that Nevisense brings measurable improvements in diagnostic accuracy, providing dermatologists with a reliable adjunct to dermoscopy in the evaluation of melanoma. With the rapid development of augmented intelligence (AuI)-based technologies and novel diagnostic tools, reader studies offer a rigorous pathway to validate performance, reduce variability in clinical decision-making, and ensure patient benefit."

Pia Renaudin, CEO of SciBase, added: "This independent publication strengthens the evidence base for Nevisense and demonstrates that it has been validated in the same rigorous way that transformative technologies in radiology and cardiology have been. We are proud to see Nevisense recognized in this way and to support dermatologists with technology that help them make better decisions and improve patient outcomes."

The article is published by Karger, one of the world's leading independent medical and scientific publishers with over 130 years of history in advancing health sciences through high-quality, peer-reviewed research. Its journal Dermatology is a globally respected platform for the latest clinical and translational advances in skin health.

The article *"The Importance of Reader Studies in Dermatology"* is available online at *Dermatology*: https://karger.com/drm/article/doi/10.1159/000548165/933589/The-Importance-of-Reader-Studies-in-Dermatology

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Aug 19 2025

Interim report

January 1 - June 30, 2025

The second quarter in figures

Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.
The loss after tax was TSEK 26,589 (15,050).
The loss per share was SEK 0.08 (0.08).
The cash flow from current operations was negative in the amount of TSEK 20,466 (15,179).
The gross margin was 66.2% (69.1%).
Electrode sales volume increased by 30% and was 18,390 (14,016) units. Repeat sales of electrodes to existing customers increased by 39%.

The first half-year in figures

Net sales were TSEK 17,648 (12,699), +39%, cleared for currency effects +43%.
The loss after tax was TSEK 54,100 (25,911).
The loss per share was SEK 0.17 (0.19).
The cash flow from current operations was negative in the amount of TSEK 46,467 (28,360).
The gross margin was 68.4% (69.5%).
Electrode sales volume increased by 30% and was 36,268 (27,868) units. Repeat sales of electrodes to existing customers increased by 29%.

Important events during the quarter

Overall sales increased by 32% (+40%, before currency effects). Sales in Germany within the skin cancer segment increased by 5% (11% in local currency). Sales in the US skin cancer market increased by 308% (345% in local currency) while the sales within the skin barrier segment decreased by 64%.
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and carries out a directed share issue of approximately MSEK 30 of which Castle Biosciences signs approximately MSEK 19. The remaining MSEK 11 was subscribed by Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB.

In the period the first order from an Italian dermatology practice was received, marking a major step forward in the company’s European expansion strategy. This follows the registration of Nevisense in Italy in February and the launch of the regional Italian version in April.

SciBase announced the launch of the next generation of Nevisense; Nevisense V. The new platform includes both hardware updates and new features specifically designed for both skin cancer diagnostics and research applications.

In the period SciBase launched a Nevisense Self-Pay Program in the US, a new initiative designed to improve patient access to the Nevisense test outside of traditional insurance coverage.

In the period a major milestone was passed with more than 300,000 Nevisense melanoma detection tests used on patients globally.

The AGM was held on June 17th, and the annual report of 2024 was published on May 23rd.

Important events after the end of the period

A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.

A new Nevisense pilot was launched at leading University in Southeast Florida.

The directed issue to Castle Biosciences was finalized and raised MSEK 19.

					July 1, 2024 -
	Apr 1 - June 30		Apr 1 - June 30		June 30, 2025	Jan 1 - Dec 31
THE GROUP	2025	2024	2025	2024	Rolling-12	2023
Net sales, SEK ths	8 791	6 641	17 648	12 699	34 653	29 705
Gross margin, %	66,2%	69,1%	68,4%	69,5%	70,2%	71,0%
Equity/Asset ratio, %	61,1%	71,8%	61,1%	71,8%	67,3%	59,4%
Net indebtness, multiple	0,64	0,39	0,64	0,39	0,49	0,68
Cash equivalents, SEK ths	23 958	43 271	23 958	43 271	23 958	11 245
Cashflow from operating activities, SEK ths	-20 466	-15 179	-46 467	-28 360	-75 490	-57 383
Earnings per share (before and after dilution), SEK	-0,08	-0,08	-0,17	-0,19	-0,33	-0,34
Shareholder's equity per share, SEK	0,10	0,28	0,10	0,39	0,16	0,21
Average number of shares, 000'*	338 296	186 303	318 503	136 449	269 021	177 994
Number of shares at closing of period, 000'*	366 296	219 538	366 296	219 538	366 296	219 538
Share price at end of period, SEK	0,38	0,51	0,38	0,51	0,38	0,41
Number of sold electrodes, pieces	18 398	14 016	36 268	27 868	70 610	62 210
Average number of employees	35	27	34	27	32	28

This interim report has not been subject to review by the Company’s auditors

This report, together with previously published interim reports, can be found in its entirety on the company's website: http://investors.scibase.se/en/reports-and-presentations

Contact person:

Michael Colérus, CFO, +46 70 341 34 72

For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Interim report

Subscribe to